

| Package | Price per Dose | Price | |
|---|---|---|---|
| 360 pills | €0,50 | €225,10 €180,08 | |
| 270 pills | €0,54 | €183,48 €146,78 | |
| 180 pills | €0,59 | €132,40 €105,92 | |
| 120 pills | €0,64 | €94,57 €75,65 | |
| 90 pills | €0,65 | €73,76 €59,01 | |
| 60 pills | €0,61 | €45,38 €36,31 | |
| 30 pills | €0,68 | €26,47 €21,17 | |
| 360 pills | €0,73 | €327,25 €261,80 Free shipping | |
| 180 pills | €0,83 | €187,26 €149,81 | |
| 120 pills | €0,94 | €139,97 €111,98 | |
| 90 pills | €1,03 | €115,38 €92,30 | |
| 60 pills | €1,04 | €77,54 €62,03 | |
| 30 pills | €1,27 | €47,27 €37,82 | |
| 360 pills | €0,98 | €442,65 €354,12 Free shipping | |
| 270 pills | €1,04 | €351,84 €281,48 Free shipping | |
| 180 pills | €1,12 | €251,58 €201,27 Free shipping | |
| 120 pills | €1,23 | €183,48 €146,78 | |
| 90 pills | €1,26 | €141,86 €113,49 | |
| 60 pills | €1,29 | €96,46 €77,17 | |
| 30 pills | €1,41 | €52,95 €42,36 | |
| 360 pills | €1,17 | €523,99 €419,19 Free shipping | |
| 180 pills | €1,38 | €310,23 €248,18 Free shipping | |
| 120 pills | €1,53 | €228,88 €183,10 Free shipping | |
| 90 pills | €1,71 | €192,94 €154,35 | |
| 60 pills | €1,86 | €139,97 €111,98 | |
| 30 pills | €2,01 | €75,65 €60,52 |
Disclaimer: This information is intended for patients in the Netherlands. It is not a substitute for professional medical advice from a clinician or pharmacist.
What happens to tuberculosis when it is not treated promptly, and how can one medicine influence the spread of the infection?
Myambutol is the brand name for ethambutol (an antimycobacterial antibiotic) used as part of combination therapy for active tuberculosis (TB) infection.
Ethambutol belongs to a class of medicines that target the bacteria causing TB, rather than viruses or fungi. It is not used alone but in a structured regimen with other anti-tuberculosis medications to improve effectiveness and reduce the chance of resistance.
In the Netherlands, the regimen commonly includes ethambutol together with other first-line medicines as part of a guided treatment plan tailored to the patient’s disease site and susceptibility testing results.
Understanding how ethambutol fits into therapy can improve adherence and safety during the course of treatment. The information below is intended to support discussions with healthcare providers and to help patients participate actively in their care.
Ethambutol acts by interfering with the synthesis of the mycobacterial cell wall. Specifically, it inhibits arabinogalactan synthesis, a key component of the wall that helps keep the bacteria intact.
Arabinogalactan is a crucial polysaccharide that links to other cell-wall components. Blocking its production weakens the cell wall and slows bacterial growth.
Pharmacologically, ethambutol is described as bacteriostatic against Mycobacterium tuberculosis, meaning the drug slows replication rather than rapidly killing bacteria. This helps allow other medicines in the regimen to reduce the bacterial population more effectively.
On a more detailed level, ethambutol inhibits arabinosyl transferases, enzymes that extend sugar chains necessary for cell-wall integrity. The resulting structural changes increase the vulnerability of bacteria to the actions of other anti-TB drugs used in combination therapy.
Combination therapy reduces the risk of resistance and improves treatment outcomes. The exact pharmacodynamic effects can vary with drug interactions and patient-specific factors such as kidney function and age.
Ethambutol is approved for use as part of combination therapy for active pulmonary tuberculosis and certain forms of extrapulmonary tuberculosis that are susceptible to the drug.
In practice, ethambutol is not used as a single agent. It is added to a regimen that usually includes other anti-tuberculosis medicines to achieve synergistic activity and minimize the development of drug resistance.
The treatment plan is determined by a clinician based on disease site, severity, drug susceptibility results, and patient factors such as age and renal function. Baseline assessments are typically performed before starting therapy.
Baseline ophthalmologic evaluation and kidney function testing are commonly recommended because of known safety considerations with ethambutol, including potential visual effects and dose adjustments related to kidney function.
Access in the Netherlands may require a prescription depending on local regulations. Always consult a clinician or pharmacist for the exact access requirements in the care setting.
Off-label use refers to prescribing a medicine for indications outside its official label. Ethambutol may be considered off-label in certain non-tuberculous mycobacterial infections or in complex drug-resistant TB scenarios when guided by an experienced clinician.
Such uses are determined on a case-by-case basis, with consideration given to drug susceptibility profiles, potential benefits, and the risk of adverse effects. Off-label regimens should be clearly documented and monitored by a specialist.
Ethambutol is sometimes included as part of multi-drug regimens for non-tuberculous mycobacterial disease in select circumstances, though exact regimens depend on the bacterial species and patient factors. Consultation with infectious disease specialists is advised in these situations.
When off-label use is contemplated, patients should be informed about the rationale, expected outcomes, potential risks, and the monitoring plan. The official patient information leaflet for ethambutol should be reviewed for standard indications and safety notes.
In all cases, the decision to pursue off-label therapy should involve shared decision-making with a clinician and pharmacist to ensure safety and appropriateness for the individual patient.
Myambutol is typically taken orally in tablet form. It may be taken with or without food, depending on tolerability and the prescribing clinician's instructions.
The dose is established by the treating clinician based on illness severity, body weight, and renal function. In the Netherlands, treatment plans are individualized and periodically reviewed to reflect response and tolerability.
Missed doses should be avoided. If a dose is missed, contact the clinician or pharmacist promptly for guidance. Do not double the next dose without professional advice, as this can increase the risk of side effects.
Treatment duration varies and is guided by the overall TB regimen, response to therapy, and drug-susceptibility results. Adherence to the full course is essential to prevent relapse or resistance.
All medications should be stored safely and kept out of reach of children. The official leaflet provides storage instructions, including temperature recommendations and any special handling requirements.
Contraindications include known hypersensitivity to ethambutol or to any of the components of the medicine. Severe optic neuritis or certain eye conditions may warrant avoidance or careful use with monitoring.
Renal impairment can affect the drug’s clearance; dose adjustments or close monitoring may be necessary in kidney disease. The medicine should be used with caution in patients with reduced kidney function, and regular testing is usually advised.
Pregnancy and breastfeeding: information regarding safety is limited. Potential benefits and risks must be weighed by a clinician. If pregnancy occurs during treatment, inform the healthcare provider promptly to discuss options.
Allergic reactions, though uncommon, require immediate medical attention. Seek urgent medical help if signs such as facial swelling, throat tightness, or breathing difficulties develop.
Concurrent use with other medicines may alter effects or increase side effects. A full medication list should be shared with the clinician or pharmacist before starting ethambutol therapy.
Baseline and periodic eye examinations are essential due to the risk of optic neuritis and visual changes. Tests typically include visual acuity and color vision assessments, with follow-up monitoring during therapy.
Renal function should be monitored, as ethambutol is excreted by the kidneys. If kidney function declines, dose adjustments or changes to the regimen may be required to maintain safety and effectiveness.
Regular assessment of clinical response to therapy, as well as any adverse effects, is advised. Laboratory monitoring may include routine blood tests and assessments for liver or kidney function in prolonged treatment courses.
Patients should report any new or worsening eye symptoms promptly so that therapy can be reviewed. Eye symptoms may progress if therapy is continued unchecked.
During pregnancy or breastfeeding, treatment decisions should involve discussions about potential risks and benefits, with careful consideration by the healthcare team.
Ethambutol may interact with other medicines that affect kidney function or are cleared by the kidneys. A pharmacist should review current medicines to assess potential interactions and adjust therapy if needed.
Alcohol intake should be discussed with the clinician, as it can contribute to liver stress when used with certain TB medicines. The overall regimen may require lifestyle considerations to minimize adverse effects.
No strict dietary restrictions are commonly required with ethambutol, but meals can be used to improve tolerability if stomach upset occurs. Always follow the prescribing clinician’s guidance on administration relative to meals.
Disclose all medicines, including over-the-counter drugs and supplements, to avoid interactions that could affect drug levels or safety. A pharmacist should review all substances before starting ethambutol therapy.
The following table summarizes common uses and notes for ethambutol alongside other first-line TB medicines. Values are for general guidance and should be confirmed with a healthcare professional.
| Drug | Primary use | Notes on safety | Typical monitoring |
|---|---|---|---|
| Ethambutol (myambutol) | Active TB infection as part of a combination regimen | Optic neuritis risk; adjust for kidney function | Eye exams; kidney function tests |
| Isoniazid | Active TB and latent TB infection in many cases | Liver enzyme effects; peripheral neuropathy risk | Liver function tests; vitamin B6 status |
| Rifampicin | Broad antibacterial activity against TB; cornerstone of therapy | Drug interactions due to enzyme induction; orange body fluids | Liver tests; complete medication review |
| Pyrazinamide | First-line TB in initial phase | Joint pain; liver effects | Renal function; liver function |
General information and guidance are provided. For individualized advice, consult a healthcare professional.
Myambutol can be taken with or without food, depending on tolerability and the instructions from the prescriber. If stomach upset occurs when taken on an empty stomach, taking it with a small amount of food may help. Do not alter the prescribed schedule without medical advice.
If a dose is missed, contact the clinician or pharmacist promptly for guidance. Do not double the next dose unless advised. Consistent dosing supports steady drug levels and treatment effectiveness.
Ethambutol is used as part of a longer regimen for tuberculosis. The exact duration depends on the disease site, drug susceptibility, and response to therapy. The full course should be completed as directed by the clinician.
Moderation is generally advised; however, alcohol may interact with other TB medicines. The clinician should be consulted about any limitations during treatment to reduce potential risks.
Ethambutol may cause changes in vision, including color vision changes and reduced visual acuity. Baseline eye tests are typically performed, with follow-up assessments during therapy. Seek urgent medical attention if sudden vision changes occur.
Any new or worsening vision symptoms should be reported to a clinician promptly. A formal eye examination may be required, and therapy adjustments could be necessary to prevent lasting damage.
Information on safety during pregnancy is limited. The decision to use ethambutol during pregnancy should involve a careful assessment of benefits and risks by a clinician. If pregnancy occurs during treatment, inform the healthcare provider promptly.
Breastfeeding considerations require discussion with a clinician. The amount excreted into breast milk is not fully characterized; a risk-benefit assessment should be performed before continuing therapy while nursing.
Potential interactions with other medicines exist, particularly those affecting kidney function or carried by similar pathways. A complete medication review should be performed by a clinician or pharmacist before starting therapy.
Kidney function influences ethambutol exposure. Dose adjustments or closer monitoring may be required in kidney impairment. The treating clinician will determine whether such adjustments are needed.
Check the official patient information leaflet or ask a pharmacist or physician for the Netherlands-specific guidance. Local rules may apply to access and dispensing of ethambutol.
14–21 days. Free from €182,34 .
5–9 days. €27,35
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
